2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101743
    Elucaine 25314-87-8 98%
    Elucaine is a muscarinic acetylcholine receptor antagonist with anti-ulcerative activity.
    Elucaine
  • HY-101744
    Ipsalazide 82101-17-5 98%
    Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.
    Ipsalazide
  • HY-101745
    Rocastine 91833-49-7 98%
    Rocastine is a selective, nonsedating H1 antagonist, acting as an antihistamine.
    Rocastine
  • HY-101749
    WAY127093B racemate 145743-63-1 98%
    WAY127093B racemate is the racemate of WAY127093B. WAY127093B is an orally active phosphodiesterase IV inhibitor in guinea pigs and rats.
    WAY127093B racemate
  • HY-101751
    Chlorthenoxazine 132-89-8 98.43%
    Chlorthenoxazine is a nonsteroidal anti-inflammatory agent.
    Chlorthenoxazine
  • HY-10185R
    TG 100572 hydrochloride (Standard) 867331-64-4 98%
    TG 100572 hydrochloride (Standard) is the analytical standard of TG 100572 hydrochloride (HY-10185). This product is intended for research and analytical applications. TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572 hydrochloride (Standard)
  • HY-10198R
    Navarixin (Standard) 473727-83-2 98%
    Navarixin (Standard) is the analytical standard of Navarixin (HY-10198). This product is intended for research and analytical applications. Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
    Navarixin (Standard)
  • HY-103167
    CGH2466 dihydrochloride 1177618-54-0 98%
    CGH 2466 dihydrochloride is an orally active adenosine A1, A2B and A3 receptor antagonist with the IC50 values of 19 nM, 21 nM, and 80 nM respectively. CGH 2466 dihydrochloride inhibits p38 MAPK (IC50 = 187~ 400 nM) and phosphodiesterase type 4D (IC50 = 22 nM). CGH 2466 dihydrochloride displays potent anti-inflammatory effects both in vitro and in vivo, and can be used for research on asthma and chronic obstructive pulmonary disease (COPD).
    CGH2466 dihydrochloride
  • HY-10320R
    Doramapimod (Standard) 285983-48-4 98%
    Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM.
    Doramapimod (Standard)
  • HY-103272
    iMAC2 335166-36-4 98%
    iMAC2 is a potent MAC inhibitor with an IC50 of 28 nM and an LD50 of 15000 nM. iMAC2 shows anti-apoptotic effect. iMAC2 blocks cytochrome c release.
    iMAC2
  • HY-10328R
    Neflamapimod (Standard) 209410-46-8 98%
    Neflamapimod (Standard) is the analytical standard of Neflamapimod (HY-10328). This product is intended for research and analytical applications. Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.
    Neflamapimod (Standard)
  • HY-103388
    NCX 466 1262956-64-8 98%
    NCX 466 is an orally active COX-1 and COX-2 inhibitor that exhibits anti-inflammatory and analgesic effects. Additionally, NCX 466 acts as a NO donor, exerting anti-inflammatory and antioxidant effects by improving microcirculation. NCX 466 significantly reduces the levels of transforming growth factor-β (TGF-β) and oxidative stress markers (such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)), and it decreases leukocyte recruitment during inflammation by reducing myeloperoxidase (MPO) activity, thereby preventing bleomycin (HY-108345)-induced pulmonary fibrosis in mice.
    NCX 466
  • HY-10343R
    Sotrastaurin (Standard) 425637-18-9 98%
    Sotrastaurin (Standard) is the analytical standard of Sotrastaurin. This product is intended for research and analytical applications. Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.
    Sotrastaurin (Standard)
  • HY-10358R
    MK-2206 dihydrochloride (Standard) 1032350-13-2 98%
    MK-2206 dihydrochloride (MK-2206 2HCl) (Standard) is the analytical standard of MK-2206 dihydrochloride (HY-10358). This product is intended for research and analytical applications. MK-2206 dihydrochloride is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia.
    MK-2206 dihydrochloride (Standard)
  • HY-10402R
    Losmapimod (Standard) 585543-15-3 98%
    Losmapimod (Standard) is the analytical standard of Losmapimod. This product is intended for research and analytical applications. Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
    Losmapimod (Standard)
  • HY-10403R
    PH-797804 (Standard) 586379-66-0
    PH-797804 (Standard) is the analytical standard of PH-797804 (HY-10403). This product is intended for research and analytical applications. PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC50=26 nM and Ki=5.8 nM for p38α; Ki=40 nM for p38β) and does not inhibit JNK2.
    PH-797804 (Standard)
  • HY-10404A
    Dilmapimod tosylate 937169-00-1 98%
    Dilmapimod tosylate is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod tosylate
  • HY-10404R
    Dilmapimod (Standard) 444606-18-2 98%
    Dilmapimod (Standard) is the analytical standard of Dilmapimod. This product is intended for research and analytical applications. Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod (Standard)
  • HY-10405R
    Pamapimod (Standard) 449811-01-2
    Pamapimod (Standard) is the analytical standard of Pamapimod. This product is intended for research and analytical applications. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment.
    Pamapimod (Standard)
  • HY-10405S
    Pamapimod-d4 1246814-57-2 98%
    Pamapimod-d4 (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment.
    Pamapimod-d4
Cat. No. Product Name / Synonyms Application Reactivity